Alexandra Gerlach, Senior Content Producer

Avacincaptad pegol intravitreal solution is a prescription eye injection used to treat geographic atrophy.

Presence of leptomeningeal disease is associated with poorer treatment outcomes and quality of life for patients with breast cancer.

Rezpegaldesleukin is designed to balance the body’s immune system response through activation of regulatory T-cells.

Vietnam war trauma continues to affect veterans’ health 50 years later.

The therapeutic vaccine could provide patients with a non-surgical alternative to traditional treatment approaches.

The decision offers patients with antimicrobial resistance, who have limited or no treatment options, a new alternative.

The quadruple treatment was active and safe as initial therapy for older patients with transplant-ineligible multiple myeloma.

Ming-Hei Tai, PharmD, BCOP, shares his concerns about the AQUILA trial and use of daratumumab for smoldering multiple myeloma.

The Trop-2-tagreting antibody drug conjugate facilitated improved intracranial penetration with favorable tolerability.

Diabetic macular edema (DME) is the leading cause of new blindness in the US.

The study results build on the “obesity paradox,” which suggests that patients with cancer and obesity have better outcomes.

Prescription stimulant dispensing was greatly impacted by the COVID-19 pandemic and drug shortages.

In the study, 50% of the deaths amongst patients were linked to central nervous system-related causes.

Rising seasonal viruses and emerging concerns emphasize the need for public awareness and prevention.

Expert weighs in on data from the AQUILA trial and Johnson & Johnson's approval request for daratumumab for smoldering multiple myeloma.

Continuous dosing of ribociclib was associated with better tolerability and outcomes.

Digoxen is the active ingredient found in the foxglove plant and is commonly used to treat heart failure.

Children and adults with cancer have differing immune system responses, mutational burdens, and tissue microenvironments.

The overall survival data were immature at the primary analysis of the study.

As lung cancer cases rise, there is a significant need for therapeutic options that meet the challenges and needs of individual patients.

This follows the approval of everolimus tablets for patients aged 1 and older in January 2025.

Isatuximab is a CD38-targeting monoclonal antibody that has demonstrated significant clinical success in improving minimal residual disease rates and progression-free survival.

Endocrine therapy in combination with CDK4/6 inhibitors improves patients’ outcomes, but many still become treatment resistant.

Tucatinib is an oral HER2-targeting tyrosine kinase inhibitor that was approved by the FDA in 2020.

Presence of comorbidities in older patients with breast cancer complicates treatment decisions.

Rates of invasive breast cancer or death were 50% lower with adjuvant trastuzumab emtansine compared with trastuzumab alone.

Endocrine-immune-based therapies yielded favorable objective response rates but had limited impact on pathological complete response.

These data suggest the potential efficacy of immune checkpoint inhibitors with anthracycline-based chemotherapy.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

The caps on insulin and yearly out-of-pocket drug costs remain unaffected by this decision.